FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033131866> ?p ?o ?g. }

• W3033131866 endingPage "839" @default.
• W3033131866 startingPage "838" @default.
• W3033131866 abstract "Background: Ultra-rare genetically defined IL-1 mediated autoinflammatory diseases (AIDs) include mevalonate kinase deficiency (MKD), tumor necrosis factor receptor associated periodic syndrome (TRAPS), cryopyrinopathies (CAPS) and deficiency of the IL-1 receptor antagonist (DIRA). These disorders start perinatally, the clinical disease manifestations include systemic inflammation; and late diagnosis and inappropriate treatment cause irreversible organ damage. The varying skills of treating rheumatologists and paediatricians illustrate the need for management guidance, however criteria for validated methodology is geared towards common diseases with more heterogeneous pathogenesis. Objectives: The focus of this systematic review includes the evaluation of the existing literature and the evaluation of existing EULAR methodology for use in the ultra-rare diseases with defined pathomechanisms, CAPS, TRAPS, MKD and DIRA Methods: EULAR standardized operating procedures were followed during the review, including a meeting of experts to discuss key words, inclusion/exclusion criteria and PICO questions. Three fellows established the protocol of the review under the supervision of the EULAR methodologist and PubMed, Embase, and Cochrane databases were searched up to September 30, 2019. Results: We found 1582 articles for CAPS, 1109 articles for TRAPS,1741 articles for MKD and 557 articles for DIRA. Duplications, animal models and basic science studies, conference papers, systematic reviews/meta-analysis and articles not in English language is excluded. If we excluded case reports (n<4), then 72 articles for CAPS, 40 articles for TRAPS,44 articles for MKD and 1 article for DIRA should be included for full text evaluation and data extraction (Figure 1). However among the case reports, patients excluded achieved complete remission, assessed by clinical criteria and biomarkers. Of the studies included only few randomized studies for CAPS, TRAPS, MKD, and DIRA and would achieve higher level of evidence (Figure 1). Figure 1. Flow-charts of systematic review for CAPS, TRAPS and MKD. Conclusion: CAPS, TRAPS, MKD and DIRA are monogenic diseases with defined pathways and outcomes that include inflammatory remission based on clinical and biomarker data. Current methodological evaluations for genetically complex diseases undervalue the published evidence in case reports that report on remission and IL-1 biomarkers. We suggest that case studies that include hard outcomes including inflammatory remission, and open label withdrawal studies that are both backed by biomarkers could be allowed to be included and be considered for a stronger evidence level. References: [1]van der Heijde D, Aletaha D, Carmona L, et al 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations Annals of the Rheumatic Diseases 2015;74:8-13. [2]Gattorno M, Hofer M, Federici S, Vanoni F, Bovis F, Aksentijevich I, Anton J, Arostegui JI, Barron K, Ben-Cherit E, Brogan PA, Cantarini L, Ceccherini I, De Benedetti F, Dedeoglu F, Demirkaya E, Frenkel J, Goldbach-Mansky R, Gul A, Hentgen V, Hoffman H, Kallinich T, Kone-Paut I, Kuemmerle-Deschner J, Lachmann HJ, Laxer RM, Livneh A, Obici L, Ozen S, Rowczenio D, Russo R, Shinar Y, Simon A, Toplak N, Touitou I, Uziel Y, van Gijn M, Foell D, Garassino C, Kastner D, Martini A, Sormani MP, Ruperto N; Eurofever Registry and the Paediatric Rheumatology International Trials Organisation (PRINTO). Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis. 2019 Aug;78(8):1025-1032. Disclosure of Interests: Roberta Berard: None declared, micol romano: None declared, Zehra Serap Arici: None declared, David Piskin: None declared, Olcay Jones: None declared, Karen Durrant: None declared, Raphaela Goldbach-Mansky: None declared, Marco Gattorno Consultant of: Sobi, Novartis, Speakers bureau: Sobi, Novartis, Erkan Demirkaya: None declared" @default.
• W3033131866 created "2020-06-12" @default.
• W3033131866 creator A5000636712 @default.
• W3033131866 creator A5006777215 @default.
• W3033131866 creator A5032187087 @default.
• W3033131866 creator A5037962183 @default.
• W3033131866 creator A5043221241 @default.
• W3033131866 creator A5043887994 @default.
• W3033131866 creator A5046351370 @default.
• W3033131866 creator A5067354798 @default.
• W3033131866 creator A5086253529 @default.
• W3033131866 date "2020-06-01" @default.
• W3033131866 modified "2023-09-25" @default.
• W3033131866 title "FRI0482 A SYSTEMATIC REVIEW FOR THE MANAGEMENT OF THE GENETICALLY DEFINED IL-1-MEDIATED AUTOINFLAMMATORY DISEASES, CAPS, TRAPS, MKD AND DIRA" @default.
• W3033131866 doi "https://doi.org/10.1136/annrheumdis-2020-eular.6023" @default.
• W3033131866 hasPublicationYear "2020" @default.
• W3033131866 type Work @default.
• W3033131866 sameAs 3033131866 @default.
• W3033131866 citedByCount "0" @default.
• W3033131866 crossrefType "journal-article" @default.
• W3033131866 hasAuthorship W3033131866A5000636712 @default.
• W3033131866 hasAuthorship W3033131866A5006777215 @default.
• W3033131866 hasAuthorship W3033131866A5032187087 @default.
• W3033131866 hasAuthorship W3033131866A5037962183 @default.
• W3033131866 hasAuthorship W3033131866A5043221241 @default.
• W3033131866 hasAuthorship W3033131866A5043887994 @default.
• W3033131866 hasAuthorship W3033131866A5046351370 @default.
• W3033131866 hasAuthorship W3033131866A5067354798 @default.
• W3033131866 hasAuthorship W3033131866A5086253529 @default.
• W3033131866 hasBestOaLocation W30331318661 @default.
• W3033131866 hasConcept C17744445 @default.
• W3033131866 hasConcept C177713679 @default.
• W3033131866 hasConcept C189708586 @default.
• W3033131866 hasConcept C199539241 @default.
• W3033131866 hasConcept C2779473830 @default.
• W3033131866 hasConcept C71924100 @default.
• W3033131866 hasConceptScore W3033131866C17744445 @default.
• W3033131866 hasConceptScore W3033131866C177713679 @default.
• W3033131866 hasConceptScore W3033131866C189708586 @default.
• W3033131866 hasConceptScore W3033131866C199539241 @default.
• W3033131866 hasConceptScore W3033131866C2779473830 @default.
• W3033131866 hasConceptScore W3033131866C71924100 @default.
• W3033131866 hasIssue "Suppl 1" @default.
• W3033131866 hasLocation W30331318661 @default.
• W3033131866 hasOpenAccess W3033131866 @default.
• W3033131866 hasPrimaryLocation W30331318661 @default.
• W3033131866 hasRelatedWork W178155765 @default.
• W3033131866 hasRelatedWork W2001692247 @default.
• W3033131866 hasRelatedWork W2115099528 @default.
• W3033131866 hasRelatedWork W2955383188 @default.
• W3033131866 hasRelatedWork W3029969037 @default.
• W3033131866 hasRelatedWork W3161158858 @default.
• W3033131866 hasRelatedWork W4230570618 @default.
• W3033131866 hasRelatedWork W4239204192 @default.
• W3033131866 hasRelatedWork W4249380099 @default.
• W3033131866 hasRelatedWork W4252371801 @default.
• W3033131866 hasVolume "79" @default.
• W3033131866 isParatext "false" @default.
• W3033131866 isRetracted "false" @default.
• W3033131866 magId "3033131866" @default.
• W3033131866 workType "article" @default.